MedTrace Logo

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

NCT00853151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2012-04-13

Study results available
· View outcomes & findings →

Summary

Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2428757

14 mg subcutaneous injection 1 time a week for 5 weeks

DRUG

TT223

subcutaneous injection once a day for 4 weeks

DRUG

Placebo for LY2428757

subcutaneous injection 1 time a week for 5 weeks

DRUG

Placebo for TT223

subcutaneous injection once a day for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853151 on ClinicalTrials.gov